Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Wellcome Trust (306752/Z/23/Z)
Cancer Research UK (SEBCATP-2022/100009)
Leuka (2022/FuF/001)
- License Information
-
More Information
Article History
Received: 2 June 2025
Revised: 11 August 2025
Accepted: 4 September 2025
First Online: 19 September 2025
Competing interests
: KT has received stock options and research funding from Storm Therapeutics.
